Capital International Sarl Purchases New Holdings in Illumina, Inc. (NASDAQ:ILMN)

Capital International Sarl purchased a new position in Illumina, Inc. (NASDAQ:ILMN - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 68,653 shares of the life sciences company's stock, valued at approximately $9,174,000.

Other institutional investors have also added to or reduced their stakes in the company. CANADA LIFE ASSURANCE Co grew its position in shares of Illumina by 5.1% in the 4th quarter. CANADA LIFE ASSURANCE Co now owns 279,836 shares of the life sciences company's stock worth $37,382,000 after buying an additional 13,563 shares during the period. Farringdon Capital Ltd. purchased a new stake in Illumina in the fourth quarter worth about $206,000. Zacks Investment Management increased its stake in shares of Illumina by 3.5% during the fourth quarter. Zacks Investment Management now owns 23,210 shares of the life sciences company's stock valued at $3,102,000 after purchasing an additional 786 shares in the last quarter. Jump Financial LLC lifted its holdings in shares of Illumina by 260.0% during the fourth quarter. Jump Financial LLC now owns 7,865 shares of the life sciences company's stock valued at $1,051,000 after purchasing an additional 5,680 shares during the last quarter. Finally, Senvest Management LLC boosted its position in shares of Illumina by 19.5% in the 4th quarter. Senvest Management LLC now owns 1,070,292 shares of the life sciences company's stock worth $143,023,000 after purchasing an additional 174,532 shares in the last quarter. Institutional investors own 89.42% of the company's stock.

Analyst Ratings Changes

A number of research analysts have issued reports on the company. Morgan Stanley lowered their price objective on Illumina from $150.00 to $136.00 and set an "equal weight" rating for the company in a research note on Tuesday, February 11th. TD Cowen cut shares of Illumina from a "buy" rating to a "hold" rating and dropped their price target for the stock from $177.00 to $140.00 in a research note on Friday, February 7th. Royal Bank of Canada decreased their target price on shares of Illumina from $128.00 to $112.00 and set an "outperform" rating for the company in a report on Tuesday, April 8th. HSBC cut shares of Illumina from a "buy" rating to a "hold" rating and set a $100.00 price target on the stock. in a report on Friday, February 28th. Finally, Barclays decreased their price objective on shares of Illumina from $100.00 to $77.00 and set an "underweight" rating for the company in a report on Thursday, April 10th. One equities research analyst has rated the stock with a sell rating, ten have assigned a hold rating, ten have given a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $138.70.

Illumina Price Performance

Shares of NASDAQ:ILMN traded up $1.08 during midday trading on Wednesday, reaching $75.43. 539,702 shares of the company were exchanged, compared to its average volume of 2,268,173. The company has a current ratio of 1.77, a quick ratio of 1.42 and a debt-to-equity ratio of 0.63. The stock has a market cap of $11.94 billion, a PE ratio of -9.82, a price-to-earnings-growth ratio of 1.60 and a beta of 1.38. The business's fifty day moving average is $83.43 and its two-hundred day moving average is $119.36. Illumina, Inc. has a one year low of $68.70 and a one year high of $156.66.

Illumina (NASDAQ:ILMN - Get Free Report) last issued its earnings results on Thursday, February 6th. The life sciences company reported $0.86 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.92 by ($0.06). Illumina had a positive return on equity of 13.37% and a negative net margin of 27.95%. As a group, analysts predict that Illumina, Inc. will post 4.51 earnings per share for the current year.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.